Inclusion Criteria:  Male or female participants ≥65 years of age at the time of consent Participating or participated in Study C4591001, received 2 doses of 30 µg BNT162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of BNT162b2 Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease Adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study  Exclusion Criteria:  History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study Previous clinical or microbiological diagnosis of COVID-19 Previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation Previous vaccination with any coronavirus vaccine, other than those received in Study C4591001 Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study